Oncology

Erasca, Inc. has priced an upsized public offering of common stock, securing $225 million in gross proceeds. This capital infusion, at $10.00 per share, will advance the company’s pipeline of therapies for RAS/MAPK pathway-driven cancers. The funds are earmarked for research and development, supporting product candidates, and general corporate purposes, reflecting strong investor confidence.

IDEAYA Biosciences unveiled its 2026 strategic roadmap, focusing on advancing its pipeline. Key objectives include presenting darovasertib trial results for uveal melanoma, potentially supporting accelerated approval, and initiating four registrational trials. The company will also advance its antibody-drug conjugate programs, including IDE849 for neuroendocrine cancers, and explore next-generation therapies targeting MTAP pathway alterations and CDKN2A. With substantial cash reserves extending into 2030, IDEAYA is set for significant pipeline progress and potential regulatory milestones.

Summit Therapeutics has granted stock options to seventeen new employees, allowing them to purchase up to 214,331 shares at $18.66 each. These options have a ten-year term and vest over four years, designed to attract and retain talent in the competitive biopharmaceutical industry. This aligns employee interests with the company’s long-term growth and commitment to developing oncology therapies.

Telix Pharmaceuticals reports significant progress in its precision medicine portfolio, especially in oncology. Key advancements include positive Phase 3 data for TLX591-CDx (Illuccix®) in China for prostate cancer imaging, meeting its primary endpoint and paving the way for a Chinese NDA submission. The company is also nearing NDA resubmission for TLX101-CDx (Pixclara®) in the U.S. and has aligned with the FDA on CMC deficiencies for TLX250-CDx (Zircaix®) BLA. These developments highlight Telix’s strategic focus on radiopharmaceutical innovation and market expansion.

Molecular Partners will present pipeline updates and its 2025 outlook at the J.P. Morgan Healthcare Conference. CEO Patrick Amstutz will discuss advancements in their novel DARPin drug technology, focusing on oncology. The presentation, webcast live, is expected to detail clinical progress, strategic direction, and financial projections for the coming year, offering insights into the company’s innovative therapeutic approach and market potential.

SOPHiA GENETICS has launched SOPHiA DDM™ Digital Twins, an AI-powered research technology designed to revolutionize oncology. By creating virtual representations of individual patients using comprehensive data, Digital Twins simulate treatment outcomes, enabling oncologists to make more informed decisions. This allows for in silico experimentation, predicting disease progression and personalizing treatment strategies. The platform leverages a global network of patient data to provide data-driven insights. Initially for lung cancer, expansion to other cancer types is planned, marking a shift towards AI-guided precision medicine.

Genmab will acquire Merus for $97.00 per share in cash, a deal valued at approximately $8.0 billion. This acquisition adds petosemtamab, a late-stage asset with Breakthrough Therapy Designations for head and neck cancer, to Genmab’s portfolio. Petosemtamab has shown promising Phase 2 data and is currently in Phase 3 trials. Genmab anticipates the acquisition accelerating its business model transition, broadening revenue streams and being accretive to EBITDA by the end of 2029. The deal is expected to close in early 2026, pending customary approvals.

Exelixis, Inc. announced the promotion of Dana T. Aftab, Ph.D., to Executive Vice President, Research and Development. Aftab, with 25 years at Exelixis, will lead drug discovery, translational research, product development, and medical affairs. She played a critical role in developing CABOMETYX® (cabozantinib). The company aims to maximize its portfolio, including zanzalintinib. Amy Peterson, M.D., previously Executive Vice President, Product Development & Medical Affairs, has left Exelixis. Exelixis is focused on creating next-generation oncology medicines.